Key result
Circulating ApoH and ApoC3 explain ~25% of MoCA cognitive variance.
Why the study?
Mild cognitive impairment and mild behavioral impairment are overlapping prodromal states associated with dementia risk, and their relationships with circulating apolipoproteins remain unclear.
Are circulating plasma apolipoprotein profiles and an atherogenic apolipoprotein composite associated with mild cognitive and behavioral impairment in older adults?
Cross-Sectional (n=148)
Are circulating plasma apolipoprotein profiles and an atherogenic apolipoprotein composite associated with mild cognitive and behavioral impairment in older adults?
Circulating apolipoprotein profiles—specifically ApoH and an atherogenic composite of ApoB, ApoC1, and ApoC3—are inversely associated with cognitive performance in older adults and represent potential biomarkers for early cognitive dysfunction.
Answers are grounded in this paper and cite their sources.
Apolipoprotein-cognition associations in prodromal states require longitudinal validation; hypothesis-generating and should not yet change practice.
Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE ε4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.
No takes yet. Share an insight, caveat, or question.
Amrapala et al. (2026) conducted a cross-sectional in Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) (n=148). Circulating apolipoprotein profiles (ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, ApoJ) and atherogenic Apo composite (ApoB-ApoC1-ApoC3) vs. Cognitively normal controls was evaluated on Quantitative cognitive (MoCA, CERAD) and behavioral (NPI) outcomes (R-squared 20.7-28.2% of MoCA variance explained). Circulating ApoH, ApoC3, and covariates explained 20.7-28.2% of MoCA variance, while the atherogenic Apo composite was inversely associated with MoCA and CERAD memory scores.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: